| MeSH term | MeSH ID | Detail |
|---|---|---|
| Ureteral Obstruction | D014517 | 10 associated lipids |
| Rodent Diseases | D012376 | 4 associated lipids |
| Osteomyelitis | D010019 | 10 associated lipids |
| Pancreatitis | D010195 | 10 associated lipids |
| Skin Ulcer | D012883 | 6 associated lipids |
| Cysts | D003560 | 4 associated lipids |
| Urination Disorders | D014555 | 9 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Abnormalities, Drug-Induced | D000014 | 10 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Cosme A et al. | Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. | 2013 | Clin. Microbiol. Infect. | pmid:22512623 |
| Gui J et al. | [Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing]. | 2013 | Zhonghua Jie He He Hu Xi Za Zhi | pmid:24252731 |
| AvÅŸar E et al. | A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients. | 2013 | Turk J Gastroenterol | pmid:24254262 |
| Smiley R et al. | Comparative proteomics analysis of sarcosine insoluble outer membrane proteins from clarithromycin resistant and sensitive strains of Helicobacter pylori. | 2013 | J. Microbiol. | pmid:24173641 |
| Ma Y et al. | Characteristics and evaluation of an injectable clarithromycin lipid-based complex in vitro and in vivo. | 2013 | Drug Deliv | pmid:24032596 |
| Boyanova L et al. | Characterization of oral Helicobacter pylori strain by 4 methods. | 2013 | Diagn. Microbiol. Infect. Dis. | pmid:24075629 |
| Morakul B et al. | Precipitation-lyophilization-homogenization (PLH) for preparation of clarithromycin nanocrystals: influencing factors on physicochemical properties and stability. | 2013 | Int J Pharm | pmid:24076396 |
| Lally L and Mannion L | The potential for antimicrobials to adversely affect mental state. | 2013 | BMJ Case Rep | pmid:23833088 |
| Murai A et al. | Mastitis caused by Mycobacterium kansasii infection in a dog. | 2013 | Vet Clin Pathol | pmid:23808608 |
| Berghaus LJ et al. | Mutant prevention concentration and mutant selection window for 10 antimicrobial agents against Rhodococcus equi. | 2013 | Vet. Microbiol. | pmid:23915992 |
| [Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial]. | 2013 | Jpn J Antibiot | pmid:24930240 | |
| Khamraev AA et al. | [State of mucosal barrier of the stomach after Helicobacter pylori eradication and ulcer healing in patients with duodenal ulcer disease]. | 2013 | Eksp Klin Gastroenterol | pmid:24933985 |
| Nykula TD and Furleta VV | [Rationale for improved treatment of ulcerative disease complicated by chronic pyelonephritis]. | 2013 | Lik. Sprava | pmid:25095689 |
| Avci O et al. | A comparison between the effectiveness of erythromycin, single-dose clarithromycin and topical fusidic acid in the treatment of erythrasma. | 2013 | J Dermatolog Treat | pmid:21923567 |
| Sasaki H et al. | Ten-year trend of the cumulative Helicobacter pylori eradication rate for the 'Japanese eradication strategy'. | 2013 | Digestion | pmid:24356705 |
| Yuan Y et al. | Optimum duration of regimens for Helicobacter pylori eradication. | 2013 | Cochrane Database Syst Rev | pmid:24338763 |
| Ogata SK et al. | High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. | 2013 | J. Pediatr. Gastroenterol. Nutr. | pmid:23403439 |
| Morgan DR et al. | Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. | 2013 | JAMA | pmid:23403682 |
| Naserpour Farivar T et al. | Prevalence of clarithromycin-resistant Helicobacter pylori in patients with chronic tonsillitis by allele-specific Scorpion real-time polymerase chain reaction assay. | 2013 | Laryngoscope | pmid:23404672 |
| Koh WJ et al. | Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. | 2013 | Antimicrob. Agents Chemother. | pmid:23478956 |
| Komatsu S et al. | Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells. | 2013 | Biochem. Biophys. Res. Commun. | pmid:23792097 |
| Zhen-Hua Z et al. | Characterization of 23S rRNA gene mutation in primary and secondary clarithromycin-resistant Helicobacter pylori strains from East China. | 2013 | Turk J Gastroenterol | pmid:23794337 |
| Bustamante-Rengifo JA et al. | In vitro effect of amoxicillin and clarithromycin on the 3' region of cagA gene in Helicobacter pylori isolates. | 2013 | World J. Gastroenterol. | pmid:24106405 |
| Lee G et al. | Nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Natural course on serial computed tomographic scans. | 2013 | Ann Am Thorac Soc | pmid:23952847 |
| Bolhuis MS et al. | Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. | 2013 | Antimicrob. Agents Chemother. | pmid:23689722 |
| Seddik H et al. | Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study. | 2013 | Eur. J. Clin. Pharmacol. | pmid:23695545 |
| Ohe M and Hashino S | Successful treatment of recurrent follicular B-cell lymphoma with clarithromycin, prednisolone, and cyclophosphamide. | 2013 | Korean J. Intern. Med. | pmid:23682236 |
| Sadeghifard N et al. | Survey in Iran of clarithromycin resistance in Helicobacter pylori isolates by PCR-RFLP. | 2013 | Southeast Asian J. Trop. Med. Public Health | pmid:23682442 |
| Serelis J et al. | Granulomatous infection of the hand and wrist due to Azospirillum spp. | 2013 | Diagn. Microbiol. Infect. Dis. | pmid:23685031 |
| Cerqueira L et al. | Validation of a fluorescence in situ hybridization method using peptide nucleic acid probes for detection of Helicobacter pylori clarithromycin resistance in gastric biopsy specimens. | 2013 | J. Clin. Microbiol. | pmid:23596234 |
| Lim JH et al. | Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. | 2013 | Helicobacter | pmid:23305083 |
| James GD et al. | Use of long-term antibiotic treatment in COPD patients in the UK: a retrospective cohort study. | 2013 | Prim Care Respir J | pmid:23839240 |
| Dumpis U et al. | Assessment of antibiotic prescribing in Latvian general practitioners. | 2013 | BMC Fam Pract | pmid:23311389 |
| Huang CW et al. | Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan. | 2013 | Int. J. Antimicrob. Agents | pmid:23312605 |
| Liu X et al. | Clarithromycin-loaded liposomes offering high drug loading and less irritation. | 2013 | Int J Pharm | pmid:23337631 |
| Shinde DD et al. | Different effects of clopidogrel and clarithromycin on the enantioselective pharmacokinetics of sibutramine and its active metabolites in healthy subjects. | 2013 | J Clin Pharmacol | pmid:23381968 |
| Sarkeshikian SS et al. | Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial. | 2013 | Turk J Gastroenterol | pmid:23794338 |
| Jouneau S et al. | Clarithromycin stops lung function decline in airway-centered interstitial fibrosis. | 2013 | Respiration | pmid:23095475 |
| Higashida A et al. | Effectiveness of esomeprazole-based triple therapy of H. pylori in young patients in Japan. | 2013 | Scand. J. Gastroenterol. | pmid:23016956 |
| Kim MS et al. | Long-term follow-up Helicobacter pylori reinfection rate and its associated factors in Korea. | 2013 | Helicobacter | pmid:23066652 |
| Xiong LJ et al. | Detection of clarithromycin-resistant Helicobacter pylori by stool PCR in children: a comprehensive review of literature. | 2013 | Helicobacter | pmid:23067446 |
| Kupcinskas L et al. | Evolution of Helicobacter pylori susceptibility to antibiotics during a 10-year period in Lithuania. | 2013 | APMIS | pmid:23078193 |
| Tsuji D et al. | Retrospective analysis of severe neutropenia in patients receiving concomitant administration of docetaxel and clarithromycin. | 2013 | Chemotherapy | pmid:25011542 |
| Gokmen T et al. | Clarithromycin treatment in preterm infants: a pilot study for prevention of feeding intolerance. | 2013 | J. Matern. Fetal. Neonatal. Med. | pmid:23570248 |
| Semino-Mora C et al. | Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects β-catenin distribution. | 2013 | Clin. Cancer Res. | pmid:23743566 |
| Zullo A et al. | Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. | 2013 | Clin Res Hepatol Gastroenterol | pmid:23747131 |
| Markert C et al. | Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. | 2013 | Eur. J. Clin. Pharmacol. | pmid:23748747 |
| Nishizawa T et al. | Delay of second-line eradication therapy for Helicobacter pylori can increase eradication failure. | 2013 | J. Gastroenterol. Hepatol. | pmid:23701705 |
| Lands LC and Stanojevic S | Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. | 2013 | Cochrane Database Syst Rev | pmid:23765216 |
| Kwon HJ et al. | Life-threatening scrub typhus with hemophagocytosis and acute respiratory distress syndrome in an infant. | 2013 | J. Trop. Pediatr. | pmid:22735791 |